Reactions to Updated Isatuximab Data in Second-Line Multiple Myeloma
April 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their views on the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with multiple myeloma.
Selecting IO/TKI Therapy for mRCC Based on Patient Profile
April 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants their impressions of tyrosine kinase inhibitor plus immune checkpoint inhibitor trials for patients with metastatic renal cell carcinoma.
Approaches to Manage Frontline Therapy for Multiple Myeloma
March 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants how they use quadruplet or triplet frontline regimens for patients with transplant-eligible multiple myeloma. This is the first of 2 articles based on this event.
When to Use Second-Line CAR T-cell Therapy for Relapsed/Refractory DLBCL
March 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed when to use CAR T-cell therapy in the second-line setting for patients with relapsed/refractory diffuse large B-cell lymphoma and the outcomes of trials of these agents. This is the first of 2 articles based on this event.
Abbas Assesses the Use of Allogenic Transplant In MPNs
March 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with his fellow clinicians the use of allogeneic hematopoietic stem cell transplant in patients with myeloproliferative neoplasms and how ruxolitinib fits into their care.
Roundtable Discussion: Krishnan Debates the Rationale For Various Therapies in Multiple Myeloma
March 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Amrita Krishnan, MD, discussed with participants their choice of therapy for a patient with multiple myeloma who relapsed after receiving bortezomib, lenalidomide, and dexamethasone followed by autologous stem cell transplant and 2 years of lenalidomide maintenance.
Dosing and Management: Optimal Use of Tafasitamab/Lenalidomide for Relapsed DLBCL
March 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bruce D. Cheson, MD, discussed adverse event management and dosing strategies for patients receiving tafasitamab and lenalidomide for diffuse large B-cell lymphoma.
BCMA Therapies Changing Treatment in Relapsed/Refractory Multiple Myeloma
March 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses how targeting patients with relapsed/refractory multiple myeloma with B-cell maturation antigens like teclistamab is changing the treatment landscape.
Lenvatinib/Pembrolizumab Shows Survival Benefit in Endometrial Cancer
March 15th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Thomas J. Herzog, MD, discussed the results of the KEYNOTE-775 trial of lenvatinib plus pembrolizumab versus chemotherapy in patients with advanced endometrial cancer.